Cost-effectiveness of an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer in the UK

Samantha Humphreys1
James Pellissier2
Alison Jones3

1Market Access Department, Merck Sharp and Dohme Ltd, Hoddesdon, Hertfordshire, UK; 2Health Economic Statistics, Merck Research Laboratories, Upper Gwynedd, PA, USA; 3Department of Medical Oncology, University College Hospital, London, UK

Purpose: Prevention of chemotherapy-induced nausea and vomiting (CINV) remains an important goal for patients receiving chemotherapy. The objective of this study was to define, from the UK payer perspective, the cost-effectiveness of an antiemetic regimen using aprepitant, a selective neurokinin-1 receptor antagonist, for patients receiving chemotherapy for breast cancer.

Methods: A decision-analytic model was developed to compare an aprepitant regimen (aprepitant, ondansetron, and dexamethasone) with a standard UK antiemetic regimen (ondansetron, dexamethasone, and metoclopramide) for expected costs and health outcomes after single-day adjuvant chemotherapy for breast cancer. The model was populated with results from patients with breast cancer participating in a randomized trial of CINV preventative therapy for cycle 1 of single-day chemotherapy.

Results: During 5 days after chemotherapy, 64% of patients receiving the aprepitant regimen and 47% of those receiving the UK comparator regimen had a complete response to antiemetic therapy (no emesis and no rescue antiemetic therapy). A mean of £37.11 (78%) of the cost of aprepitant was offset by reduced health care resource utilization costs. The predicted gain in quality-adjusted lifeyears (QAL Ys) with the aprepitant regimen was 0.0048. The incremental cost-effectiveness ratio (ICER) with aprepitant, relative to the UK comparator, was £10,847/QAL Y, which is well below the threshold commonly accepted in the UK of £20,000–£30,000/QAL Y.

Conclusion: The results of this study suggest that aprepitant is cost-effective for preventing CINV associated with chemotherapy for patients with breast cancer in the UK health care setting.

Keywords: antiemetic therapy, emesis, CINV

Introduction

The prevention of chemotherapy-induced nausea and vomiting (CINV) is an important element of supportive care in cancer. The occurrence of CINV is distressing for patients and can interfere with their daily activities, reducing quality of life and discouraging them from continuing with chemotherapy.1–5 Patients with CINV may require unplanned outpatient or inpatient medical care, adding to the cost of cancer therapy, and lost workdays can pose an economic burden for patients and their caregivers.6–8

Successful control of CINV in the first chemotherapy cycle is associated with reduced incidence of CINV in subsequent cycles.5,9,10 In addition, patients with no emesis in the acute phase (day 1 of chemotherapy) are less likely to have emesis in the delayed phase (day 2 onward);11 therefore, preventing CINV on the first day of the first chemotherapy is important.
Antiemetic therapy is prescribed according to the perceived emetogenic potential of chemotherapy. Patients with breast cancer usually receive adjuvant polychemotherapy with an anthracycline (doxorubicin or epirubicin) plus cyclophosphamide, with or without 5-fluorouracil, and in some cases in combination or sequence with a taxane.\textsuperscript{12,13} Anthracyclines and cyclophosphamide are each classified as moderately emetogenic chemotherapy (MEC), defined as causing emesis in 30%–90% of patients not receiving prophylactic therapy. However, when administered together their emetogenicity is increased.\textsuperscript{14} European consensus guidelines published in 2010 by the Multinational Association of Supportive Care in Cancer/European Society of Medical Oncology (MASCC/ESMO) recommend antiemetic regimens for preventing CINV associated with anthracycline and cyclophosphamide-based chemotherapy that are more efficacious than those recommended for other MEC regimens.\textsuperscript{15} Moreover, recent British and American guidelines classify combined anthracycline and cyclophosphamide-based regimens as highly emetogenic chemotherapy (HEC), defined as causing emesis in >90% of patients not receiving prophylactic therapy.\textsuperscript{16,17}

For preventing acute CINV with anthracycline and cyclophosphamide-based chemotherapy, current MASCC/ESMO guidelines recommend a three-drug regimen of aprepitant (or fosaprepitant), a 5-HT\textsubscript{3} receptor antagonist (5-HT\textsubscript{3} RA), and dexamethasone on day 1.\textsuperscript{15} These guidelines recommend aprepitant on day 2 and day 3 for preventing delayed CINV.\textsuperscript{15} For other MEC regimens, the recommended MASCC/ESMO antiemetic regimen comprises palonosetron and dexamethasone on day 1 and dexamethasone on day 2 and day 3.\textsuperscript{15}

Aprepitant is a selective neurokinin-1 receptor antagonist (NK-1 RA) that significantly improves the prevention of CINV for patients receiving HEC or MEC when administered in a three-drug regimen together with a 5-HT\textsubscript{3} receptor antagonists (RA) and dexamethasone, as compared with a 5-HT\textsubscript{3} RA and dexamethasone alone.\textsuperscript{11,18–23} This aprepitant regimen was effective, compared with the control regimen, in preventing CINV for patients with breast cancer for up to four cycles of anthracycline and cyclophosphamide-based chemotherapy.\textsuperscript{21,22} Rapoport et al\textsuperscript{23} reported that this aprepitant regimen was effective in preventing CINV for a diverse population of patients with a range of tumor types, receiving a variety of MEC regimens. Significantly more patients in their trial who received aprepatant, as compared with the control regimen, reported no vomiting and complete response to antiemetic therapy.

There is considerable variation in antiemetic regimens administered in clinical practice in the UK and, despite guideline recommendations for an aprepitant regimen to prevent CINV associated with anthracycline and cyclophosphamide-based chemotherapy,\textsuperscript{15,16} combinations of agents including 5-HT\textsubscript{3} RA, dexamethasone, metoclopramide, and domperidone are often used. The objective of this cost-effectiveness analysis was to define, from the UK payer perspective, the cost-effectiveness of aprepitant, administered in combination with a 5-HT\textsubscript{3} RA, and dexamethasone, for preventing CINV in patients receiving chemotherapy for breast cancer.

### Methods

#### Overview and model design

A decision-analytic model was developed to estimate the expected costs and health outcomes over 5 days after single-day chemotherapy for breast cancer, when using an aprepitant-containing antiemetic regimen compared...
with an antiemetic regimen commonly used in UK clinical practice (Table 1). The aprepitant regimen meets current European and American antiemetic guidelines for anthracycline and cyclophosphamide-based chemotherapy, while the comparator regimen reflects current clinical practice in the UK, based on recommendations by the London Cancer New Drugs Group and feedback from UK clinicians.

The model was populated with clinical results and healthcare resource utilization from an analysis of patients with breast cancer in the clinical trial reported by Rapoport et al. The control regimen used in this clinical trial is not in line with current guidelines and is not the regimen commonly used in UK clinical practice. For this reason, we selected the UK comparator regimen as the comparator for our analysis (Table 1). Given the lack of efficacy data for the UK comparator regimen compared to the aprepitant regimen, the model assumes that the UK comparator regimen has efficacy equal to that shown by the trial comparator regimen (Table 1). We tested this assumption in sensitivity analyses varying the efficacy of the UK comparator regimen. The economic evaluation was conducted from the perspective of the UK National Health Service (NHS), in line with current clinical practice, and valued in British sterling (£). No discounting was applied to costs or health effects because of the short time horizon.

**Data sources and assumptions**

**Reference clinical trial and patient population**

The reference clinical trial used in the model was a double-blind, randomized, multinational trial of CINV preventative therapy, completed in 2008 (National Clinical Trials registry number: NCT00337727). Enrolled patients were adults with a range of tumor types who were naïve to emetogenic chemotherapy and scheduled to receive cycle 1 of single-day MEC. In this study, anthracycline and cyclophosphamide-based regimens were considered to be MEC; therefore, patients receiving these combination regimens were included. Of the 949 patients screened, 848 were randomized, with 101 (10.6%) patients excluded during screening (please refer to original publication by Rapoport et al. for further details). The average age of the 848 randomized patients was 57 years; 77% were female, and 69% were white. The most common malignancies were breast cancer (52%), colorectal cancer (20%), and lung cancer (13%). Patients were randomly assigned to receive either an aprepitant-containing regimen or the control regimen of ondansetron and dexamethasone (Table 1). The primary endpoint was the proportion of

---

**Table 1**

<table>
<thead>
<tr>
<th>Aprepitant regimen</th>
<th>UK comparator regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>At least complete response (acute)</td>
<td>At least complete response (acute)</td>
</tr>
<tr>
<td>Incomplete response (acute)</td>
<td>Incomplete response (acute)</td>
</tr>
<tr>
<td>At least complete response (delayed)</td>
<td>At least complete response (delayed)</td>
</tr>
<tr>
<td>Incomplete response (delayed)</td>
<td>Incomplete response (delayed)</td>
</tr>
<tr>
<td>Complete protection (acute)</td>
<td>Complete protection (acute)</td>
</tr>
<tr>
<td>Complete response at best (acute)</td>
<td>Complete response at best (acute)</td>
</tr>
<tr>
<td>Complete protection (delayed)</td>
<td>Complete protection (delayed)</td>
</tr>
<tr>
<td>Complete response at best (delayed)</td>
<td>Complete response at best (delayed)</td>
</tr>
</tbody>
</table>

**Figure 1** Model decision tree depicting the nine possible health states, each marked by a triangle, calculated directly from clinical trial data that were included in the model.
patients with no vomiting during 120 hours (5 days) after receiving chemotherapy, and the key secondary endpoint was the proportion of patients reporting complete response, defined as no emetic episodes and no use of rescue medication during the 5 days after initiation of chemotherapy. Self-completed patient diaries were used to record emetic episodes, use of rescue therapy, and nausea severity on a daily basis for 5 days. More than 98% of the patients completed their medication according to the protocol.

The trial included 438 patients with breast cancer, of whom 193/218 (88.5%) in the aprepitant group and 189/220 (85.9%) in the control group received anthracycline and cyclophosphamide-based chemotherapy.23 Remaining patients received a variety of MEC regimens. For the purpose of this analysis, we used results from 428 patients with breast cancer who received at least one dose of the study drug and had at least one post-treatment assessment (Merck Sharp and Dohme Ltd, data on file, 2011).23 Analysis of the subgroup of patients with breast cancer was not prespecified but was selected for this cost-effectiveness analysis to allow a homogeneous patient population. In patients with breast cancer, the efficacy of both control and aprepitant regimens was lower, while the relative efficacy with aprepitant was greater, than in patients with other tumor types, with respect to the primary and key secondary endpoints. These results could be expected, both due to the higher emetogenicity of anthracycline and cyclophosphamide-based regimens as compared with other MEC regimens and because almost all patients in the breast cancer group were women, who are known to be more susceptible to CINV.10

Resource utilization and costs

Health care resource utilization data, including health care contacts, medication, and rescue antiemetic therapy use, were based on information for patients with breast cancer enrolled in the reference clinical trial (Merck Sharp and Dohme Ltd, data on file, 2011).23 There were no differences between treatment groups in the incidence or categories of adverse events; therefore, specific adverse events were not incorporated into the model. Nonetheless, any health care resource utilization associated with adverse events would have been captured. Health care contacts included hospitalizations, emergency department visits, outpatient care by physicians and nurses, visits for laboratory tests, and home health care visits.

Costs assigned to health care resource use were derived from the Personal Social Services Research Unit for 201024 and the Department of Health NHS Reference Costs for 2009–2010.25 Drug costs were derived from the Monthly Index of Medical Specialties (May 2011),26 the British National Formulary (BNF 61, March 2011),27 and the NHS Drug Tariff (May 2011),28 and weighted based on market share (Merck Sharp and Dohme Ltd, data on file, 2012). All health care resource costs were specific to the UK.

Utilities and health outcomes

The model was populated with data from the first cycle of chemotherapy and included 5 days, counting the day of chemotherapy administration as day 1. The health outcome complete response (CR) was the key secondary endpoint in the reference clinical trial and, for the purpose of the model, was subdivided into 2 mutually exclusive health outcomes: complete protection (CP) and complete response at best (CRB). The health outcome incomplete response (IR) was assigned to patients who did not achieve CR. All outcomes are defined in Table 2. The outcomes CP, CRB, and IR were combined in the model for the acute phase (day 1) and the delayed phase (day 2–day 5) to produce nine possible health states, as depicted in Figure 1. Table 2 summarizes

<table>
<thead>
<tr>
<th>Table 2 CIINV-related health state probabilities based on modified intent-to-treat analyses of patients with breast cancer from a clinical trial of aprepitant²³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health state outcome by phase²³</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Acute phase</td>
</tr>
<tr>
<td>(day 1)</td>
</tr>
<tr>
<td>Aprepitant regimen</td>
</tr>
<tr>
<td>n = 212</td>
</tr>
<tr>
<td>Protection</td>
</tr>
<tr>
<td>Complete</td>
</tr>
<tr>
<td>Incomplete</td>
</tr>
<tr>
<td>Complete</td>
</tr>
<tr>
<td>Incomplete response at best</td>
</tr>
<tr>
<td>Incomplete response at best</td>
</tr>
<tr>
<td>Incomplete response at best</td>
</tr>
<tr>
<td>Incomplete response</td>
</tr>
<tr>
<td>Complete response at best</td>
</tr>
</tbody>
</table>

Notes: a Patients included in modified intent-to-treat analyses were those who received moderately emetogenic chemotherapy, received at least one dose of study drug, and had at least one post-treatment assessment; b complete response, defined in the reference trial as no emesis and no rescue antiemetic therapy, was subdivided into two mutually exclusive health outcomes: (1) Complete protection was defined as no emesis; no rescue antiemetic therapy; and maximum nausea <25 mm on 100 mm visual analog scale scored from 0 (no nausea) to 100 (nausea as bad as it can be); and (2) complete response at best, which describes those who achieved complete response but not complete protection. Incomplete response was defined as some emesis or some use of rescue antiemetic therapy; c the reference clinical trial included a total of 438 patients with breast cancer.23 For the purpose of this analysis, we used results for 428 patients with breast cancer who received at least one dose of study drug and had at least one post-treatment assessment; 212 of these received the aprepitant regimen and 216 received the control regimen.

Abbreviations: CIINV, chemotherapy-induced nausea and vomiting; n, number.
the probabilities for each of these health outcomes, derived from the reference trial results (Merck Sharp and Dohme Ltd, data on file, 2011).23

Measures of utility are used in health economic evaluations to summarize quality of life in a particular health state. They are reported on a scale from 0 to 1, where 0 represents death and 1 represents perfect health. The utility value for a health state and the time spent in that health state are combined to produce the quality-adjusted lifedays (QALD) or quality-adjusted lifeyear (QALY). QALDs and QALYs are commonly used by health technology appraisal agencies globally as their preferred generic measure of health-related quality of life. For the model base case (ie, the modeled scenario which is expected to most closely reflect actual clinical practice), we assigned utilities to each health state in the model, as per Grunberg et al.29

They elicited QALY scores using a visual analog scale for chemotherapy states, in the absence and presence of nausea and vomiting. We assigned a value of 0.79 to the outcome CP, which corresponds to chemotherapy with no appreciable nausea or emesis, and a value of 0.27 to IR, a state in which emesis or nausea, or both, were present. We assigned a value of 0.594 to CRB, a state including nausea but not requiring rescue therapy, by normalizing the Börjeson et al29 mild nausea utility of 0.752 to the CP state (0.752 × 0.79). Utility weights, according to health states in the acute and delayed phases, are depicted in Table 3. Five-day QALY values were calculated by multiplying the full QALY value by 5/365.

The model was used to explore other CINV-related outcomes, associated costs, and gains in QALDs and QALYs. We calculated the incremental cost effectiveness ratio (ICER) as a measure of the cost-effectiveness of the aprepitant regimen relative to the UK comparator regimen, defined as the incremental cost divided by the incremental health gain in QALYs.

Sensitivity analyses
Sensitivity analyses are commonly used to assess uncertainty in economic models by evaluating the effect of differing model parameters, such as the utility values, costs, and efficacy, on the results of the economic analysis. We varied the utility assigned to CRB and IR by $\pm$30%, and that assigned to CP between a lower bound equivalent to the CRB health state (0.594) and an upper bound of 0.90, as reported by Sun et al.31

We varied the preventative antiemetic drug costs by $\pm$20% (rescue antiemetic drug costs were not varied). In addition, we evaluated results using an alternative UK comparator regimen (Table 1) in which ondansetron is continued for an additional 2 days, as is common practice in some UK centers. Finally, we performed threshold analyses to calculate the improvement in efficacy of the UK comparator regimen required to result in ICERs of £20,000/QALY and £30,000/QALY.

A probabilistic sensitivity analysis was conducted using bootstrap resampling techniques with 1000 iterations. Results of the probabilistic sensitivity analysis are presented as a cost-effectiveness acceptability curve, which illustrates the probability of the aprepitant regimen being cost-effective at different “willingness-to-pay” thresholds. Healthcare resource utilization by model health state was varied, according to the observed discrete distributions for each type of healthcare contact. Using the Grunberg et al29-based utility weights, utilities were varied using the resulting discrete distribution suggested by the trial population.

Analyses were performed using Microsoft Excel 2003 (Microsoft Corp, Redmond, WA, USA).

Results
Health outcomes
During 5 days after the first cycle of chemotherapy, 64% of patients receiving the aprepitant regimen and 47% of those receiving the comparator regimen had either CRB or CP against CINV (Merck Sharp and Dohme Ltd, data on file, 2011) (Table 4).23 More patients receiving the aprepitant regimen, versus the comparator regimen, remained emesis-free (70% versus 53%) and CINV-free (61% versus 43%) over the 5-day study period. The mean number of emetic events over the 5-day assessment period was 18.9% lower among patients treated with the aprepitant regimen than with the comparator regimen.

The predicted gain in QALDs with the aprepitant regimen was 0.35 (Table 4), which equates to a
gain of 0.0048 QALYs. There were no hospital days reported for the aprepitant arm, whereas 15 days were reported in the comparator arm amongst 3/216 (1.4%) of patients.

### Base case costs and cost-effectiveness results

The projected drug and healthcare resource costs for the aprepitant and UK comparator regimens are presented in Table 4. As compared with the UK comparator regimen in the base case scenario, an average of £37.11 (78%) of the cost of aprepitant is offset by the reduction in health care resource utilization costs. Use of the aprepitant regimen was associated with an additional cost of £28 for each emesis-free day gained and £22 for each CINV-free day gained. The ICER with aprepitant, relative to the UK comparator, was £10,847/QALY.

### Sensitivity analyses results

The results of sensitivity analyses demonstrate that ±30% changes in utility values for IR and CRB have minimal impact on the cost-effectiveness of aprepitant (Table 5). While the model is more sensitive to changing the utility values for

<table>
<thead>
<tr>
<th>Health outcome measure</th>
<th>Aprepitant regimen (n = 212)</th>
<th>UK comparator regimen (n = 216)</th>
<th>Absolute difference&lt;sup&gt;b&lt;/sup&gt; (relative difference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean number emetic events&lt;sup&gt;c&lt;/sup&gt;</td>
<td>2.11</td>
<td>2.61</td>
<td>–0.49 (–18.9%)</td>
</tr>
<tr>
<td>Complete response&lt;sup&gt;d&lt;/sup&gt;</td>
<td>63.7%</td>
<td>46.8%</td>
<td>16.9% (36.2%)</td>
</tr>
<tr>
<td>Emesis-free over 5-day cycle</td>
<td>69.8%</td>
<td>52.8%</td>
<td>17.0% (32.3%)</td>
</tr>
<tr>
<td>Mean number emesis-free days&lt;sup&gt;e&lt;/sup&gt;</td>
<td>4.3</td>
<td>3.9</td>
<td>0.4 (9.3%)</td>
</tr>
<tr>
<td>CINV-free over 5-day cycle</td>
<td>60.8%</td>
<td>42.6%</td>
<td>18.3% (42.9%)</td>
</tr>
<tr>
<td>Mean number CINV-free days&lt;sup&gt;f&lt;/sup&gt;</td>
<td>3.9</td>
<td>3.4</td>
<td>0.5 (13.7%)</td>
</tr>
<tr>
<td>No impact on daily life due to nausea and vomiting</td>
<td>69.8%</td>
<td>56.5%</td>
<td>13.3% (23.5%)</td>
</tr>
<tr>
<td>Quality-adjusted life days</td>
<td>3.10</td>
<td>2.75</td>
<td>0.35 (12.6%)</td>
</tr>
</tbody>
</table>

### Table 5 Results of a sensitivity analysis varying QALY weights for the trial outcome measures

<table>
<thead>
<tr>
<th>Health state</th>
<th>QALY weight Base case</th>
<th>Lower bound</th>
<th>Upper bound</th>
<th>ICER (£/QALY) Lower bound</th>
<th>Upper bound</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete response</td>
<td>0.27</td>
<td>0.189</td>
<td>0.35</td>
<td>£9,440</td>
<td>£12,746</td>
</tr>
<tr>
<td>Complete response at best</td>
<td>0.594</td>
<td>0.416</td>
<td>0.772</td>
<td>£10,434</td>
<td>£11,293</td>
</tr>
<tr>
<td>Complete protection</td>
<td>0.79</td>
<td>0.594</td>
<td>0.90</td>
<td>£18,200</td>
<td>£8,842</td>
</tr>
</tbody>
</table>

**Notes:**<sup>a</sup>The data shown here are from breast cancer patients who received the clinical trial control regimen in the reference clinical trial.<sup>23</sup> For the purpose of this analysis, we have used this data as the best estimate of the efficacy of the UK comparator regimen, given the lack of efficacy data for the UK comparator regimen in comparison with an aprepitant regimen;<sup>b</sup>difference represents aprepitant regimen value minus comparator regimen value;<sup>c</sup>mean number over 5 days;<sup>d</sup>complete response includes patients with complete response at best or complete protection;<sup>e</sup>outpatient care includes visits to primary care physicians or medical specialists, visits for laboratory tests not mandated by the study protocol, home health care, and emergency room visits.<sup>23</sup><sup>e</sup>Abbreviations: CINV, chemotherapy-induced nausea and vomiting; £, pound sterling; HCR, health care resource; QALY, quality-adjusted life year; UK, United Kingdom.
CP, the cost-effectiveness of the aprepitant regimen remains below the threshold of £20,000/QALY over the range of utility values tested. A reduction of 20% in antiemetic regimen drug costs reduces the ICER with aprepitant, relative to the UK comparator regimen, from £10,847/QALY to £826/QALY, while a 20% increase in drug costs increases the ICER to £20,868/QALY.

The efficacy of the UK comparator regimen was assumed in the base case analysis to be equivalent to that of the clinical trial control regimen. Threshold analysis results indicate that the efficacy of the UK comparator would need to improve by 9.9% or 16.2% for the ICER to reach a threshold of £20,000/QALY or £30,000/QALY, respectively.

The cost-effectiveness acceptability curve indicates that the probability of the aprepitant regimen being cost-effective, compared with the UK comparator regimen, is 79% and 92% at “willingness-to-pay” thresholds of £20,000/QALY and £30,000/QALY, respectively (Figure 2).

With use of the alternative UK comparator regimen (Table 1), an average of £57.47 (121%) of the cost of aprepitant is offset by reduced health care resource utilization costs. The aprepitant regimen is thus cost-saving compared with the alternative UK regimen.

**Discussion**

The aprepitant regimen had a positive impact on health outcomes and quality of life for patients with breast cancer receiving chemotherapy. In the base case analysis, an average of £37 or 78% of the cost of aprepitant was offset due to the better efficacy of the aprepitant regimen compared with the regimen representing the UK standard of care. The results of the cost-effectiveness analysis demonstrated that an aprepitant regimen, when compared with standard UK clinical practice, is cost-effective for preventing CINV in patients receiving chemotherapy for breast cancer with an ICER of £10,847/QALY. This ICER is well below the willingness-to-pay threshold of £20,000–£30,000/QALY that is commonly accepted in the UK. When the utility values, costs, and efficacy assigned to the regimens were varied in sensitivity analyses, the aprepitant regimen remained cost-effective, with ICERs below or equal to £20,000/QALY, with the exception of increasing the antiemetic regimen drug costs by 20%, which resulted in an ICER of £20,868/QALY.

Optimizing control of CINV in the first cycle of chemotherapy is already an important goal of cancer supportive care and is associated with a reduced incidence of CINV in subsequent chemotherapy cycles. Use of aprepitant was associated with lower health care resource utilization compared with the comparator regimen, mainly due to fewer
hospitalizations in the aprepitant group in the reference trial. Successful prevention of CINV has previously been shown to reduce outpatient health care resource use, including visits to a specialist and the emergency room.\textsuperscript{6,34}

When compared with the alternative UK comparator regimen in which ondansetron is continued twice daily on day 2 and day 3 of the regimen, the aprepitant regimen was both more effective and cost-saving. This is likely because the efficacy of the alternative comparator regimen was not increased to account for the addition of ondansetron on day 2 and day 3, whereas the cost of the additional ondansetron was incorporated. This may be a reasonable assumption, however, because ondansetron has limited efficacy in preventing delayed CINV.\textsuperscript{35–38}

One of the strengths of this study is the consistency of results across all outcomes in the model and in the sensitivity analyses. The aprepitant regimen applied in the study model is that used in clinical trials of anthracycline plus cyclophosphamide-based chemotherapy and other MEC regimens\textsuperscript{21,23} and represents the current standard of care for prevention of CINV associated with anthracycline plus cyclophosphamide-based chemotherapy as recommended by evidence-based, consensus guidelines for Europe and the US.\textsuperscript{15,17} Some patients included in this analysis received MEC regimens and, although the aprepitant regimen is not recommended for these patients in clinical guidelines, aprepitant is licensed for use with all MEC regimens.

There are some limitations in this economic analysis. The study published by Rapoport et al in 2010\textsuperscript{22} was used as the reference trial, as it contains the most recent data regarding use of apreitant in patients receiving chemotherapy for breast cancer and because the patient population was not limited to anthracycline and cyclophosphamide-based chemotherapy. However, there were no UK centers included in this study\textsuperscript{23} while the observed resource utilization was assumed to be applicable to a UK setting. Data from an earlier trial, which included patients with breast cancer restricted to anthracycline and cyclophosphamide-based chemotherapy,\textsuperscript{21} were not included in this analysis. We assumed for the purpose of the analysis that the efficacies of the trial and UK comparator regimens were the same. However, the UK regimen includes dexamethasone and metoclopramide in the delayed phase and so might be more effective than the trial comparator regimen in which only ondansetron is used in the delayed phase.\textsuperscript{15}

The efficacy of the UK comparator regimen may have been underestimated; therefore, we varied the efficacy in sensitivity analyses and found that the efficacy would have to increase by 16% for the ICER to reach £30,000/QALY.

There are other potential limitations to this study. First, our analyses were based on UK list prices while actual prices may differ. Second, the results of the analysis were sensitive to hospitalizations, of which there were none in the apreitant group and 0.069 hospital days per patient in the trial control group; therefore, if fewer hospitalizations are assumed with standard UK practice, the ICER increases. Third, the selectivity of patient eligibility criteria in the apreitant clinical trials could also limit applicability to real-life clinical practice; for example, administration of an apreitant regimen is untested for patients who experienced CINV in previous cycles of chemotherapy. Finally, we examined only one cycle of chemotherapy, and the cost-effectiveness of the apreitant regimen over multiple chemotherapy cycles is uncertain. However, data from a prior study indicate that the antiemetic efficacy of the apreitant regimen is maintained over multiple cycles of chemotherapy.\textsuperscript{22}

Decision-analytic modeling has previously been used to study the cost-effectiveness of apreitant for CINV prevention with MEC in Belgium.\textsuperscript{29} The apreitant regimen was compared for patients receiving anthracycline and cyclophosphamide-based chemotherapy with the control regimen used in the Rapoport et al trial.\textsuperscript{22} The Belgian model, which drew on clinical data from a different trial\textsuperscript{22} and used health state preference measures different from those in the present study, found that the apreitant regimen was associated with a gain of 0.014 QALYs and was the dominant approach from the perspective of the Belgian health care payer.

Further study is required to evaluate the use of apreitant in the UK for preventing CINV associated with MEC over multiple cycles and in patients who experienced CINV in previous chemotherapy cycles. In addition, data are needed on the efficacy of the apreitant regimen compared with current UK clinical practice. Finally, as our model only included direct medical costs of CINV, it would be of interest to also assess other medical costs and indirect costs, such as costs associated with missed work days for patients and their caregivers.

Control of CINV remains an important goal for patients receiving chemotherapy. In this time of growing demands on finite health care resources, assessment of the cost-effectiveness of therapies is becoming increasingly necessary. The apreitant regimen has been shown to improve the control of CINV associated with a variety of MEC regimens, including those used among patients with breast cancer. The results of this study suggest that the use of apreitant is cost-effective for preventing CINV associated with cycle 1 of single-day chemotherapy for patients with breast cancer in the UK health care setting.
Acknowledgments
This study was funded by Merck and Co, Inc, Whitehouse Station, NJ, USA. Medical writing and editorial assistance was provided by Elizabeth V Hillyer. This assistance was funded by Merck Sharp and Dohme Corp, a subsidiary of Merck and Co, Inc, Whitehouse Station, NJ, USA.

Disclosure
Samantha Humphreys and James Pelissier are employed by Merck Sharp and Dohme Ltd and Merck and Co, Inc, respectively. Alison Jones is a consultant to several pharmaceutical companies, including Merck Sharp and Dohme Ltd, Roche, Novartis, Celgene Corp, GlaxoSmithKline, Amgen, and Pfizer Inc. The authors have full control of all primary data and agree to allow the journal to review their data if requested.

References


